Dr Louis Nisbet leads BioCity forward

BioCity Nottingham appoints new chairman

Louis Nisbet has become chairman of BioCity Nottingham in the UK. He will oversee the expansion of BioCity’s services to cater for increasing demand from both UK and international tenants. The recent arrival of former AstraZeneca and Pfizer employees launching new ventures, as well as the rapid growth of several existing tenants, makes the BioCity bioscience cluster an attractive central UK business location.

Marlow-based Nisbet is a venture partner with Kurma BioFund, Paris. His early pharmaceutical career in drug discovery research with Roche, Glaxo and Smith Kline gives him a global insight into the issues surrounding the development and commercialisation of new healthcare products and businesses. He will devote time in Nottingham with fellow Board directors to addressing the needs of new life science companies, in particular their financing requirements.

Nisbet said: ‘We will be looking to work with our clients and the large pharmaceutical companies, as well as private investors, to find innovative solutions to facilitate partnerships and financing that will suit everyone.’

You may also like

Finance

BioCity predicts proliferation of workspace amid life science ventures boom

The UK's life science incubator has released the Life Science Start-Up Report with in-depth analysis of emerging businesses
Finance

BioCity makes FT 1000 list of Europe's fastest growing companies

The list identified BioCity and one of the companies on one of its sites in top 200 in the UK for fastest growth
Research & Development

£1.4m to boost growing space for life sciences companies

A £1.4million investment will provide more space for life sciences companies at a Nottingham Enterprise Zone site, thanks to funding from the D2N2 Local Enterprise Partnership, Boots and MediCity
Research & Development

BioCity to support Pfizer scientists facing redundancy

Package of support could lead to new start-up ventures for staff from Sandwich, Kent plant
Manufacturing

Lonza appoints Hans Trees as Global Head of Communications

Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
Manufacturing

AlzeCure licenses Alzheimer’s candidate ACD680 to Lilly in deal worth up to $1bn

AlzeCure Pharma has entered a global licensing and collaboration agreement with Eli Lilly for its Alzheimer's disease candidate ACD680, securing a $10m upfront payment and potential milestone payments exceeding $1bn
Finance

GSK acquires Nuvalent for $10.6bn to accelerate NSCLC pipeline with FDA-reviewed ROS1 and ALK inhibitors

GSK has agreed to acquire clinical-stage oncology company Nuvalent for $10.6bn, securing two late-stage next-generation kinase inhibitors — zidesamtinib and neladalkib — currently under FDA review for potential 2026 approval in non-small cell lung cancer
Subscribe now